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Abstract
Inherited mutations of the BRCA1 gene predispose to breast, ovarian, and other cancers. The role of the BRCA1 gene in the
maintenance of chromosomal integrity is linked to a number of biological properties of its protein product, including transcriptional
regulation. In the present study, we have used suppression subtractive hybridisation (SSH) to identify genes induced by BRCA1 by
comparing control MCF7 breast carcinoma cells (driver) with MCF7 cells ectopically expressing BRCA1 (tester) and generated a
forward subtracted cDNA library. We screened 500 putative positive clones from this library. Two hundred and ten of these clones
were positive by differential screening with forward and reverse subtracted probes and the 65 cDNA clones which showed more than
fivefold increase were selected for sequencing analysis. We clustered 46 different genes that share high homology with sequences in
the GenBank/EMBL databases. Among these, 30 were genes whose function had been previously identified while the remaining 16
clones were genes with unknown functions. Of particular interest, BRCA1 gene induces the expression of genes encoding DNA
repair proteins RAD21 and MSH2, ERBB2/HER2 interacting protein ERBIN, meningioma-associated protein MAC30, and a
candidate ovarian tumour-suppressor OVCA1. Northern and Western blot analyses confirmed that the expression of these five genes
are up-regulated following BRCA1 overexpression in MCF7 and UBR60-bcl2 cells. This is the first study reporting a set of BRCA1-
induced genes in breast carcinoma cells by the SSH technique. We suggest that some known genes identified in this study may
provide new insights into the tumour-suppressor function of BRCA1.
 2002 Elsevier Science (USA). All rights reserved.
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Germ-line mutations in the BRCA1 tumour-sup-
pressor gene predispose carriers to breast and ovarian
cancers and account for approximately 50% of inherited
breast cancers [1]. BRCA1 gene encodes a 220 kDa
multifunctional nuclear phosphoprotein involved in
different cellular pathways including cellular response to
DNA damage, cell cycle, growth suppression, apoptosis
induction, ubiquitin ligation, and transcription regula-
tion [2]. Several functional regions have been described
in BRCA1: an N-terminal RING finger domain, two
nuclear localisation signals, and two BRCA1 carboxyl
terminal (BRCT) motifs at the carboxyl terminus.
BRCA1 is the main component of the BRCA1-associ-
ated genome surveillance complex (BASC) which serves
as a sensor for DNA damage. BASC comprises tumour
suppressors and DNA damage repair proteins MSH2,
MSH6, MLH1, ATM, BLM, the RAD50–MRE11–
NBS1 protein complex, and DNA replication factor C
[3,4]. In addition, the carboxyl terminal of BRCA1 acts
as a strong transcriptional activator when fused to a
heterologous DNA binding domain [5]. BRCA1 co-pu-
rifies with RNA polymerase II holoenzyme complex,
suggesting that it is a component of core transcription
machinery [6]. BRCA1 also interacts with several tran-
scription factors such as p53, CtIP, c-myc, ZBRK1,
ATF, E2F, and signal transducer STAT1 [7] and mod-
ulates their activity. These findings, together with the
interaction of BRCA1 with histone deacetylases
(HDACs) and the SWI/SNF-related chromatin remod-
elling complex, imply that transcriptional regulation is
one of the main functions of BRCA1 [8]. In addition,
nearly all germ-line BRCA1 mutations involve trunca-
tion or loss of the C-terminal BRCT transcriptional
activation domain, suggesting that transcriptional reg-
ulation is a critical function of the BRCA1 gene. Our
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purpose in this study was to identify the genes whose
expression is regulated by BRCA1 and therefore con-
tribute to a better understanding of its cellular func-
tions. We used MCF7 breast carcinoma cell line which
has low endogenous BRCA1 expression level and
maintains wild-type p53 [9]. We compared the expres-
sion profile of control MCF7 cells with MCF7 cells ec-
topically expressing BRCA1 by performing SSH. We
generated a subtracted cDNA library and identified
novel BRCA1-induced genes as candidate mediators of
tumour suppression by BRCA1.
Materials and methods
Cell lines and cell culture. MCF7 breast carcinoma cells (American
Type Culture Collection) and UBR60-bcl2 cells were maintained in
Dulbeccos modified Eagles medium (DMEM) supplemented with
10% fetal calf serum, 1mM glutamine, 10U/ml penicillin G, and 10lg/
ml streptomycin, at 37 C in 5% CO2-containing atmosphere. The
UBR60-bcl2 cell line (a gift from Dr. Paul Harkin) which expresses
BRCA1 under the control of tetracycline-regulated promoter has been
previously described [10].
Plasmids and transfections. pCMVmycBRCA1 was constructed by
subcloning the full-length BRCA1 insert from pCR3.BRCA1 (pro-
vided by Dr. Barbara Weber) into pCMVmyc vector (Clontech labo-
ratories, Palo Alto, CA). pCR3.BRCA1 was cut withHindIII, the ends
were filled with Klenow, and SalI linkers were ligated into the ends.
The plasmid was digested with SalI/NotI and the BRCA1 cDNA was
cloned into pCMVmyc vector (Clontech). MCF7 cells were grown to
80% confluency 24 h prior to electroporation. Briefly, cells were har-
vested with trypsin, washed twice with ice-cold calcium and magne-
sium-free PBS, and re-suspended in ice-cold PBS. Plasmid DNA was
added (30lg=15 106 cells/cuvette) and electroporation was carried
out at 950lF, 0.22 kV/cm (t ¼ 19–22ms) (BioRad Gene Pulser).
pEGFP-N2 (Clontech) was used as a control plasmid to calculate the
transfection efficiency using the same experimental conditions. Total
RNA and protein extractions were performed 24 h after transfection.
Annexin V staining. Binding of Annexin V to the cell surface, which
is an early indication of apoptosis, was determined with the Annexin
V-PE stain (PharMingen, BD Biosciences). Cells were washed twice
with cold PBS and then incubated in the dark in 100ll binding buffer
(0.01M Hepes, pH 7.4, 0.14M NaCl, and 0.25mM CaCl2) containing
5ll Annexin V-PE stain per coverslide. The coverslides were washed
with binding buffer and fixed in 1ml of 90% cold ethanol for 30min
under dim light. After washing with PBS, Hoechst staining (300lg/ml
final concentration) was performed for 5min in the dark. The cover-
slides were extensively washed with H2O and mounted onto 80%
glycerol droplet. As a positive control for apoptosis, MCF7 cells were
treated under 50 J/m2 ultraviolet light and the same experimental
conditions were applied.
Western blot analysis. Cells were harvested using RIPA lysis buffer
(10mM Tris–Cl, pH 8.0, 1mM EDTA, 150mM NaCl, 1% NP-40, 1%
NaDOC, and protease inhibitors). Equal amounts of protein extracts
were loaded in 10% (for MSH2 and cytokeratin 18) or 5% (for
BRCA1, Ab-1) SDS–polyacrylamide gels and transferred onto
polyvinylidene difluoride (PVDF) membranes. After overnight incu-
bation at 4 C in blocking solution (TBS-T: 20mM Tris–HCl, pH 7.6,
0.137M NaCl, 0.5% Tween 20, and 3% milk) membranes were incu-
bated for 2 h at room temperature with mouse anti-human BRCA1
monoclonal (Ab-1, Oncogene Research Products), mouse anti-human
MSH2 monoclonal (Ab-1, Oncogene Research Products), or cytoker-
atin 18 (JAR13 clone, a gift from Dr. D. Bellet, IGR, France) anti-
bodies. Blots were washed three times for 10min in TBS-T and
incubated with the secondary antibody (Horseradish peroxidase-con-
jugated anti-mouse IgG, 1:2000, Santa Cruz Biotechnology) for 1 h at
room temperature with constant shaking. After extensive washing,
chemiluminescence detection was carried out with the Amersham ECL
detection kit according to manufacturers instructions.
RNA isolation for cDNA subtraction. Total RNA was prepared
with TRI Reagent (Sigma). mRNA was isolated from total RNA with
poly(A) Spin mRNA Isolation Kit (New England Biolabs) according
to manufacturers specifications. For removal of DNA contamination
from RNA samples, the MessageClean Kit (GenHunter) was used
according to manufacturers instructions.
Suppression subtractive hybridisation (SSH). SSH was performed
with PCR-Select cDNA Subtraction Kit (Clontech) as described by the
manufacturer with minor modifications. In brief, 3.5lg polyðAÞþ
RNA from MCF7 cells electroporated with pCMVmyc used as the
driver and 3.5 lg from pCMVmycBRCA1-transfected cells was used as
the tester to construct a forward subtracted library. Reverse subtrac-
tion was also performed where tester cDNA was derived from MCF7
electroporated with pCMVmyc and driver cDNA derived from MCF7
electroporated with pCMVmycBRCA1 using the same experimental
conditions. SSH was performed with double-strand tester and driver
cDNAs. Primary PCR condition was 94 C for 30 s, 66 C for 30 s, and
72 C for 90 s for 30 cycles in 25 ll reaction volume. One microliter of
1/10th diluted primary PCR product was added into a new PCR tube
for a second round of PCR. The secondary PCR condition was 94 C
for 30 s, 68 C for 30 s, and 72 C for 90 s for 15 cycles. All PCR and
hybridisation steps were performed on a Perkin–Elmer 9600 thermal
cycler.
Cloning of cDNA mixture. The final PCR-generated forward sub-
tracted cDNA mixture, enriched for BRCA1 up-regulated sequences,
was cloned into the cloning vector pGEM-T Easy (Promega) and
transformed into supercompetent Escherichia coli strain JM109. The
transformed bacteria were plated on 150mm ampicillin agar plates
containing 100mM IPTG and 50mg/L X-Gal and bacteria were grown
overnight at 37 C. Plates were then incubated further at 4 C until
blue/white staining could be clearly distinguished.
Differential screening of clones. The PCR-Select Differential
Screening Kit (Clontech) was used to screen the subtracted cDNA li-
brary to analyse the differentially expressed sequences according to
manufacturers recommendations. Five hundred white clones were
picked randomly, inoculated into sterile 96-well plates containing LB
medium with ampicillin, and grown overnight shaking at 37 C. Then
1 ll of each bacteria culture was used to amplify the cDNA inserts with
SP6 and T7 universal primers. The PCR products were then trans-
ferred into 96-well plates and denatured in equal amount of NaOH and
1.5 ll of each sample was blotted onto two nylon membranes (Hybond
Nþ) in an identical order. Negative hybridisation controls cDNA1 and
cDNA2 (provided by the manufacturer), and BRCA1 cDNA were
included as control in the blots. The forward and reverse subtracted
cDNA pools in SSH steps were used as probes which were labelled
with ½a-32PdCTP using Random Primers DNA Labeling System
(Clontech). Two identical blots were hybridised with either forward or
reverse probes with the same number of cpm for each pair and signal
intensity was measured by phosphorimaging (Bio-Rad Molecular
Imaging System). Two hundred and ten clones which showed more
than fivefold increase in signal intensity were again dotted onto
membranes and differential screening was repeated two further times.
Sequencing and homology search. All sequencing reactions were
performed on double-stranded plasmid templates with T7 and SP6
primers. Sequencing reactions were carried out with the Big Dye ter-
minator cycle sequencing kit and analysed with the ABI 377 DNA
sequencer. Partial cDNA sequences were compared with entries in the
GenBank/EMBL database using the BLAST homology search pro-
gram at http://www.ncbi.nlm.nih.gov/blast/.
Northern blot analysis. Total RNA was isolated with TRI Reagent
(Sigma). Thirtylg of total RNA samples was resolved by formalde-
hyde gel electrophoresis, run overnight at 50V, and then transferred to
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nylon membrane (Hybond Nþ). Purified cDNA inserts were labelled
with HexaLabel Plus Kit (MBI Fermentas) and separated by Quick
Spin columns (Boehringer–Mannheim). Membrane hybridisation was
carried out overnight at 65 C in hybridisation buffer (0.5M phosphate
buffer, pH 7.2, 7% SDS, 1mM EDTA, 1% BSA, and 10 lg/ml salmon
sperm DNA, and yeast total RNA) containing at least 107 cpm
½a-32PdCTP-labelled cDNA PCR products as probes per membrane.
Membranes were sequentially washed in 2 SSC and 0.5% SDS, 1
SSC and 0.5% SDS, and 0:2 SSC and 0.5% SDS at 68 C and the
filters were exposed to X-ray film with an intensifying screen at )70 C.
Results
Ectopic expression of BRCA1 in MCF7 breast carcinoma
cells
MCF7 cells were transiently transfected with either
pCMVmycBRCA1 or a control plasmid pCMVmyc
lacking BRCA1 insert. The transfection efficiency, veri-
fied by pEGFP-N2 reporter plasmid, was approximately
40%. Under these conditions, less than 1–2% of cells were
apoptotic, as tested by Annexin V staining at 24 h, fol-
lowing transfection with either BRCA1 or control plas-
mid (data not shown). Thus, at a transfection efficiency of
40%, no more than 5% of BRCA-1 expressing cells were
apoptotic. This indicated that ectopically expressed
BRCA1 was not significantly cytotoxic to MCF7 cells
under test conditions. BRCA1 or control plasmid-trans-
fected cells were examined for the BRCA1protein level by
Western blot analysis. The results of two representative
experiments are shown in Fig. 1. Both controlMCF7 cells
(lane 1) and the cells transfected with control plasmid
without BRCA1 insert (lane 2) demonstrated endogenous
BRCA1 protein. As shown in Fig. 1 (experiment 1) ec-
topically expressed BRCA1 protein level was similar to
endogenous BRCA1 level, suggesting that transient
transfection resulted in a significant increase in total
BRCA1 levels in pCMVmycBRCA1-transfected MCF7
cells (lane 3). Taken together, these results indicated that
it was possible to increase BRCA1 levels in MCF7 by
transient transfection, without compromising cellular
integrity.
Generation of a subtracted library and screening of
differentially expressed clones
We used suppression subtractive hybridisation (SSH)
technology to identify genes that are differentially ex-
pressed in BRCA1-transfected MCF7 cells. SSH was
performed with the double-strand tester (MCF7/
pCMVmycBRCA1) and driver (MCF7/pCMVmyc)
cDNAs (forward subtraction). Reverse subtraction was
also performed where tester cDNA was derived from
pCMVmyc-transfected MCF7 cells and driver cDNA
derived from pCMVmycBRCA1-transfected cells. Fol-
lowing SSH, differential screening was performed with
these forward and reverse subtracted probes in order to
identify differentially expressed genes. Five hundred
clones were selected at random from the forward sub-
tracted library enriched for BRCA1 up-regulated se-
quences and the cDNA inserts were amplified. The PCR
products were then blotted onto membranes together
with control cDNAs and probed with the forward and
reverse subtracted cDNA pools. Two hundred and ten
of them were screened positive by differential screening
with forward and reverse subtracted probes and 65
cDNA clones which showed more than fivefold increase
were selected for sequencing analysis (Table 1). Fig. 2
shows an example of duplicate dot blots hybridised with
forward (Fig. 2A) and reverse subtracted cDNA probes
(Fig. 2B), respectively. Control experiments indicated
the subtraction allowed the enrichment of BRCA1
cDNA. As expected, the negative hybridisation controls
cDNA1 and cDNA2 were not hybridised.
BRCA1-induced genes in breast cancer cells form several
distinct functional classes
To characterise the 65 differentially expressed clones,
the inserts were partially sequenced and the output se-
quences, compared to the GenBank/EMBL database in
order to find homologies with already known genes.
Eight clones yielded poor sequence data and eleven
genes were represented more than once in the library
(Table 1). Overall, 57 clones showed more than 90%
Table 1
Summary of the analysed clones
Number
Analysed putative positive clones after SSH 500
Confirmed by differential screeninga 210




a The cDNA clones which showed more than 5-fold induction were
selected for sequencing.
b Eight clones yielded poor sequence data and eleven genes were
represented more than once in the library.
Fig. 1. Ectopic expression of BRCA1 in MCF7 breast carcinoma cells.
MCF7 cells electroporated without any plasmid (lane 1), cells trans-
fected with control plasmid pCMVmyc (lane 2), and pCMVmycBR-
CA1 plasmid (lane 3) are shown. Total protein extracts were prepared
and analysed for BRCA1 by Western blot using Ab-1 antibody specific
to BRCA1. Blots shown are representative of Western blot analysis
from six separate experiments.
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homology to known genes. As shown in Table 2, we
associated 30 of the genes to a known or putative
function: 5 in transcriptional regulation, 3 in interme-
diate metabolism, 3 in ubiquitin-mediated proteolysis, 2
in chromatin organisation, 3 in DNA repair, 2 in re-
ceptor-mediated signalling, and 2 in cytoskeletal orga-
nisation. The others were involved in amino acid or ion
transport, cell–cell and cell–ECM interaction, endosome
or vesicle-trafficking, and N-glycan biosynthesis. The
Cdc7 protein kinase which is involved in the initiation of
DNA synthesis was also induced by BRCA1. The
function of the remaining 16 genes was unknown.
Confirmation of BRCA1-induced genes by Northern and
Western blot analysis
Several BRCA1-induced genes reported here are
known to be involved in DNA repair (RAD21, MSH2);
[11,4] and chromosomal structure maintenance
(RAD21, CDC7, SGT1, and HMG1); [12–15]. This
observation strongly suggests that at least some of the
effects attributed to BRCA1 for chromosomal stability
are mediated by these genes. To further analyse their
BRCA1-regulated expression, we analysed RAD21 and
MSH2 expression in two different cell lines. Both
RAD21 and MSH2 were up-regulated following over-
expression of BRCA1 in MCF7 cells (Figs. 3A and B) as
well as in the UBR60-bcl2 cell line following BRCA1
induction (Fig. 3C).
Northern blot assays, using both MCF7 and UBR60-
bcl2 cells, demonstrate that BRCA1 induces ERBIN
expression (Fig. 4). OVCA1 that was identified as a
candidate tumour-suppressor gene was also studied. The
levels of OVCA1 mRNA transcripts (1.1 and 2.3-kb
species) were low in MCF7 cells and BRCA1 overex-
pression caused induction of both transcript forms (Fig.
4A). Finally, MAC30 transcript, whose expression has
been reported to be decreased in meningiomas, sch-
wannomas, and neurofibromas [16] was also induced in
MCF7 as well as UBR60-bcl2 by BRCA1 (Fig. 4B).
These studies performed with UBR60-bcl2 cells that
stably express BRCA1 at modest levels in an inducible
manner [10] confirm and validate our results obtained
with a transient expression approach to identify poten-
tial BRCA1 target genes.
Discussion
In the present study, we have used SSH technology to
generate a library of partial-length cDNAs representing
differentially expressed mRNAs in BRCA1-overex-
pressing MCF7 cells. SSH combines subtractive hy-
bridisation with PCR to generate a population of PCR
fragments enriched for sequences from genes expressed
differentially. SSH-mediated cDNA enrichment allows
the equalisation of wide differences in abundance of
different transcript species. Consequently, differentially
expressed transcripts of low abundance can be cloned
[17]. Using this approach we were able to identify 46
genes that are up-regulated as a result of BRCA1
overexpression in breast cancer cells.
Several studies have previously reported the identifi-
cation of BRCA1 target genes in osteosarcoma [10],
colorectal cancer [18], mouse BRCA)/) embryonic stem
[19], and human embryonal kidney epithelial [20] cells.
None of the genes that we report here have been iden-
tified in these previous studies. This could be due to the
fact that we used a breast cancer cell line to identify
potential BRCA1 target genes by the highly sensitive
SSH technique.
We report that several DNA damage response
(RAD21, MSH2, ASF1A, and CDC7) and chromo-
somal structure maintenance (RAD21, ASF1A, CDC7,
SGT1, and HMG1) genes are positively regulated tar-
gets of BRCA1. As BRCA1-deficient cells suffer from
both DSB repair deficiency and chromosomal instability
[21], at least some of these defects may be attributed to
inefficient expression of these target genes in the absence
of functional BRCA1.
Several other genes (such as SGT1, UbE3A, and
PSMB4) are involved in ubiquitin-mediated protein
degradation. This may be expected since BRCA1 itself
(together with BARD1) functions as an E3 ubiquitin
ligase [2,22,23]. The involvement of BRCA1 in ubiqu-
itin-mediated protein degradation could help explain the
multiplicity of biological roles ascribed to this protein,
including coordination of DNA repair-related events.
Other genes involved in distant cellular processes such as
intermediate metabolism, cell–cell interaction, receptor-
mediated signalling, endosome-trafficking, or cytoskel-
etal organisation also appear to be up-regulated by
BRCA1 (Table 2). In this context, BRCA1 seems to act
like another tumour-suppressor gene, namely p53 which
Fig. 2. Differential screening of SSH-selected cDNA clones with for-
ward (A) and reverse (B) subtracted probes. Selected cDNA inserts
were PCR-amplified from forward subtracted cDNA library, enriched
for BRCA1 up-regulated sequences, spotted in two identical mem-
branes, and hybridised with ½a-32PdCTP-labelled forward or reverse
subtracted cDNA probes. Rows A–H; test cDNA samples, Rows H3:
negative PCR control, H5–H6: cDNA1, H9–H10: cDNA2 as negative
control cDNAs, H7–H8: BRCA1, and H12: NaOH+water). For ex-
ample E2 cDNA showed no significant increase (1.76-fold), but C3
cDNA (zinc finger protein, LZK1) displayed 7.0-fold increase. The
signal intensities were measured by phosphorimager.
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Table 2
List of BRCA1 up-regulated genes in MCF7 breast carcinoma cells




Amino acid transport Solute carrier family 38, member 2 (SLC38A2) XM_028311 9 1 800 bp
Cell–cell interaction CD24 antigen (small cell lung carcinoma
cluster 4 antigen) (CD24)
XM_087865 29 1 800 bp
Cell–ECM interaction Integrin, b1 (fibronectin receptor, b polypeptide)
(ITGB1), transcript variant 1E
NM_133376 6 1 800 bp
Chaperon Dystonia 1, torsion (autosomal dominant;
torsin A) (DYT1)
NM_000113 11 1 1.1 kb
Chromatin assembly/DNA
repair and response
Anti-silencing function 1A (ASF1A) AF279306 13 2 500 bp
Chromatin structure High-mobility group (nonhistone chromosomal)
protein 1 (HMG1)
BC003378 9 1 650 bp
Cytoskeleton organisation Vinculin (VCL), transcript variant meta-VCL NM_014000 7 1 800 bp
Cytoskeleton organisation Capping protein (actin filament) muscle Z-line, b BC008095 14 1 800 bp
DNA repair MutS homolog 2, colon cancer, nonpolyposis
type 1 (E. coli) (MSH2)
XM_034901 9 1 600 bp
DNA repair RAD21 homolog (S. pombe) (RAD21) NM_006265 11 1 500 bp
Vesicle-trafficking SEC22, vesicle-trafficking protein
(Saccharomyces cerevisiae)-like 1
BC001364 11 2 900 bp
Endosome-trafficking Suppressor of Kþ transport defect 1 (SKD1) NM_004869 9 1 700 bp
Intermediate metabolism Fructose-1,6-bisphosphatase 1 (FBP1) NM_000507 9 1 500 bp
Intermediate metabolism Galactose-4-epimerase, UDP- (GALE) XM_032314 9 1 400 bp
Intermediate metabolism NADH dehydrogenase (ubiquinone)
1b subcomplex 9
BC007672 9 1 750 bp
Ion transport ATPase, Naþ/Kþ transporting, b3 polypeptide
(ATP1B3)
NM_001679 10 1 800 bp
N-Glycan biosynthesis Dolichyl-phosphate N-acetylglucosaminephospho-
transferase 1 (GlcNAc-1-P transferase)
BC008817 6 1 550 bp
Nuclear envelope protein Thymopoietin (TMPO) U18271 11 1 900 bp
Protein kinase/DNA
synthesis/Meiosis
Cdc7 (CDC7) AF015592 11 1 800 bp
Receptor-mediated signalling Erbb2 interacting protein (ERBB2IP) (ERBIN) NM_018695 6 1 700 bp
Receptor-mediated signalling G protein a stimulating activity polypeptide 1
(GNAS)
BC002722 13 1 700 bp
Transcription regulation C3HC4-type zinc finger protein (LZK1)
(Dif3 homolog)
NM_024835 7 1 700 bp
Transcription regulation Activity-dependent neuroprotector (ADNP) NM_015339 9 1 500 bp
Transcription regulation Hypoxia-inducible factor 1, a subunit inhibitor
HIF1AN (FIH-1)
XM_030426 7 1 700 bp
Transcription regulation Sex comb on midleg-like 1 (Drosophila) (SCML1) NM_006746 9 1 600 bp
Transcription regulation Kelch-like protein C3IP1 (C3IP1) XM_086284 7 2 400 bp
Mitochondrial stress response D-Prohibitin (Bap37) AF178980 8 1 500 bp
Ubiquitin-mediated proteolysis Suppressor of G2 allele of SKP1, S. cerevisiae,
homolog of (SGT1)
NM_006704 8 1 450 bp
Ubiquitin-mediated proteolysis Ubiquitin protein ligase E3A, transcript variant
2 (UbE3A)
NM_000462 9 1 600 bp
Ubiquitin-mediated proteolysis Proteasome subunit, b type, 4 (PSMB4) XM_047881 9 1 800 bp
Unknown KIAA0725 protein (KIAA0725) XM_049445 12 1 1.0 kb
Unknown Acidic (leucine-rich) nuclear phosphoprotein
32 family, member B (ANP32B)
NM_006401 9 1 800 bp
Unknown Candidate tumour-suppressor OVCA1 (OVCA1) NM_080822 12 2 1.0 kb
Unknown Hypothetical protein (MAC30), mRNA XM_031536 17 2 900 bp
Unknown Similar to tumour metastasis-suppressor; longevity
assurance (LAG1, S. cerevisiae) homolog 2
XM_065847 12 2 600 bp
Unknown DNA sequence from clone RP11-165J3 on
chromosome 9
AL583839.1 16 1 800 bp
Unknown Hypothetical protein FLJ23375 (FLJ23375) NM_024956 16 2 500 bp
Unknown Hypothetical protein MGC2714 (MGC2714) NM_032299 8 1 500 bp
Unknown Hypothetical protein BC008322 (LOC92106) NM_138381.1 8 3 700 bp
Unknown Hypothetical protein FLJ20060 XM_005467.4 12 2 700 bp
Unknown CG2277 gene product (LOC221294) XM_166297.1 7 1 500 bp
Unknown Hypothetical protein MGC4767 (MGC4767) XM_045844 10 1 700 bp
Unknown KIAA1007 XM_168026.1 11 2 700 bp
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also up-regulates a high number of genes involved in
many different cellular processes [24]. Although we have
not investigated these target genes in tumours yet, we
notice that 10 of the 46 genes (22%) that we report here
(RAD21, ERBB2IP, UbE3A, FBP1, KIAA0725,
TMPO, PSMB4, CD24, MSH2, and ATP1B3) are
among markers of a poor prognosis gene expression
signature identified by DNA microarray analysis of
early primary breast tumours [25]. Therefore, we believe
that we identified a large set of BRCA1 target genes that
may be involved in BRCA1-mediated cellular processes
as well as breast carcinogenesis.
In relation to BRCA1-related breast/ovarian carci-
nogenesis, we further analysed the expression of ERBIN
Table 2 (continued)




Unknown Clone FLB9213 PRO2474 AF130088 11 1 700 bp
Unknown Chromosome 5 clone CTD-2085H24 AC025447 10 1 800 bp
Unknown CGI-48 protein (LOC51096) NM_016001 13 1 750 bp
Fig. 4. BRCA1 mediated up-regulation of genes involved in cell signalling or tumour suppression in MCF7 cells and UBR60-bcl2 cells. (A) ERBIN,
MAC30, and OVCA1 transcript induction in MCF7 cells (B) ERBIN and MAC30 induction in UBR60-bcl2 cells. Cells were treated and Northern
blotting was performed as described in Fig. 3.
Fig. 3. BRCA1 induces up-regulation of RAD21 and MSH2 in MCF-7 (A, B) and UBR60-bcl2 (C) cells following BRCA1 induction. (A) Northern
blot with total RNA from MCF7 cells transfected with control plasmid pCMVmyc (lane V) and pCMVmycBRCA1 plasmid (lane B) confirms
BRCA1-mediated induction of RAD21 expression. (B) Western blot analysis of MSH2 protein levels confirms induced expression of MSH2. Cy-
tokeratin 18 was used for equal protein loading control. (C) Northern blot of total RNA from UBR60-bcl2 cells with inducible BRCA1 expression
shows over-expression of ectopic BRCA1, RAD21, and MSH2 following tetracycline withdrawal ()T) at 24 h. Ethidium bromide staining shows
equal RNA loading in each lane. ‘‘FI’’ indicates fold induction.
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and OVCA1. ERBIN, an ERBB2/HER2-binding pro-
tein which locates this receptor to the basolateral
membrane [26], was also up-regulated by BRCA1.
Overexpression of ERBB2/HER2 is frequently observed
in breast cancers and its overexpression is associated
with poor tumour prognosis [27]. Although it is not
known whether ERBIN is able to inhibit ERBB2/HER2
activity, its deregulation results in the mislocalisation of
the receptor [26]. This raises the possibility that ERBIN
deficit resulting from inactivation of BRCA1 could lead
to a loss of epithelial homeostasis, and in consequence,
pathological disorganisation in breast carcinoma. An-
other gene, namely OVCA1 which we show to be
up-regulated by BRCA1, was initially identified as a
candidate ovarian tumour-suppressor gene located on
chromosome 17p13.3 [28]. This locus displays frequent
LOH in both ovarian and breast cancers [29] and
OVCA1 was reported to display reduced expression in
breast and ovarian cancers [30]. In addition, ectopic
expression of OVCA1 causes a dramatic reduction in
cell proliferation in association with accelerated cyclin
D1 degradation [30]. Even if additional studies are
needed, these observations strongly suggest that BRCA1
mediates its tumour-suppressor functions through a
large set of downstream genes involved in DNA repair,
receptor-mediated signalling, and ovarian cancer sup-
pression.
In conclusion, we have identified 46 genes whose
expression levels are up-regulated as a result of BRCA1
overexpression in breast cancer cells. The properties of
several of these genes are consistent with putative tu-
mour-suppressor functions in breast neoplasia. To our
knowledge, our study is the first to report BRCA1-in-
duced genes in breast carcinoma cells with the SSH
technique. It will now be important to construct a
complete profile of BRCA1-regulated genes in order to
achieve an integrated view of all the functional events
regulated by BRCA1, and to assess how expression of
these genes is affected by the BRCA1 status of cells.
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